de.mpg.escidoc.pubman.appbase.FacesBean
Deutsch
 
Hilfe Wegweiser Impressum Kontakt Einloggen
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Zeitschriftenartikel

How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression

MPG-Autoren

Bschor,  Tom
Max Planck Institute of Psychiatry, Max Planck Society;

Berghöfer,  Anne
Max Planck Institute of Psychiatry, Max Planck Society;

Ströhle,  Andreas
Max Planck Institute of Psychiatry, Max Planck Society;

Kunz,  Dieter
Max Planck Institute of Psychiatry, Max Planck Society;

Adli,  Mazda
Max Planck Institute of Psychiatry, Max Planck Society;

Müller-Oerlinghausen,  Bruno
Max Planck Institute of Psychiatry, Max Planck Society;

Bauer,  Michael
Max Planck Institute of Psychiatry, Max Planck Society;

Externe Ressourcen
Es sind keine Externen Ressourcen verfügbar
Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Bschor, T., Berghöfer, A., Ströhle, A., Kunz, D., Adli, M., Müller-Oerlinghausen, B., et al. (2002). How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. Journal of Clinical Psychopharmacology, 22(4), 427-430.


Zitierlink: http://hdl.handle.net/11858/00-001M-0000-000E-A1A5-C
Zusammenfassung
There is compelling evidence from placebo-controlled studies that lithium augmentation is an effective strategy in the acute and continuation treatment of refractory unipolar major depression. Authors prospectively investigated the 1-year outcome of 22 subjects diagnosed with unipolar major depression who had participated in a 4-month placebo-controlled, double- blind continuation study of lithium augmentation without relapse. At the end of the double-blind phase, the blinded medication (lithium in 14 patients, placebo in 8 patients) was tapered off over a 1-week period, while the antidepressant was continued at the same dosage for another 4 weeks. Subsequently, the antidepressant was gradually discontinued over a 4-week period. Clinical status was assessed at regular follow-up visits. During the open 6-month follow-up period, seven subjects suffered an affective recurrence, five of whom had received lithium during the placebo-controlled, double-blind phase of the study. Study data suggest that active medication should be maintained for at least 1 year after successful lithium augmentation in patients with unipolar major depressive disorder